NCI’s clinical assay development program: supporting translation of biomarkers for cancer diagnosis

Clicks: 23
ID: 332278
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #84 of 408 articles by views in JNCI Journal of the National Cancer Institute

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 408 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract This commentary illustrates the National Cancer Institute’s (NCI) use of structured phased award programs (R21/R33 and later UH2/UH3 grants) to provide academic laboratories with continuous, milestone-driven funding to refine unvalidated assay prototypes into robust Laboratory Developed Test(s) (LDTs) and potentially commercialized, Food and Drug Administration (FDA)-approved In vitro Diagnostics (IVDs). Supported assays typically involve molecular or cellular biomarkers and are analytically validated in the first phase, and then clinically validated using well-annotated human biospecimens from existing studies or trials to demonstrate association with relevant clinical endpoints. These assays may test for predictive biomarkers (associated with treatment response or resistance) or prognostic biomarkers (associated with natural disease progression and patient outcomes), as long as they provide clinically useful information. Funding support through these programs has led to commercial partnerships and subsequent larger-scale clinical trials resulting in approved IVDs. These programs have also developed LDTs to serve patients with rare forms of cancer, to screen and enroll clinical trial participants for early-stage drug testing (e.g., identifying individuals whose tumors carry rare mutations that match a new drug's target), and to accelerate the clinical adoption of innovative technologies for detection and diagnosis. This commentary is organized as a perspective followed by historical examples of successful projects and concluding remarks on the requirements for rigorous diagnostics development.
Reference Key
openalex_W7221674512 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Sumana M Dey, Sanita Bharti, Ana I Robles, Lyndsay N. Harris, Tracy Lively
Are you one of these authors? Claim your profile
Journal JNCI Journal of the National Cancer Institute
Year 2026
DOI
10.1093/jnci/djag386
URL
https://doi.org/10.1093/jnci/djag386
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.